Hi, Rajeev.
That Merck/Schering-Plough merger described in the link you gave is a great example of how to handle THAT transaction. But that does not necessarily apply to ANY OTHER transaction.
While we can learn from studying such examples, each transaction is unique. Tax effects can turn on a single factor that may be different from the "example" transaction, producing quite different results for the shareholder.
Can you tell us WHICH two companies were involved in the merger you are asking about? A link to the website of at least one of them should help us find the Investor Relations page there to read and (hopefully) understand the details of THAT transaction. Also, please tell us which company's shares you held before the transaction; it's hard to get the right perspective from which to view the transaction unless we know that. The view is different from Company A, Company B, Company A's shareholders, Company B's shareholders - and for an interested bystander, such as a CPA trying to understand the whole picture.
We did discuss a cash-and-stock merger here recently. See the thread, "How do I handle the recent merger of Pfizer and Wyeth", started by " snipped-for-privacy@old.net" on 10/18/09. As I said above, the facts of each case are unique, so this is not likely to completely answer your questions, but it might help. (We've not heard back from oldman, so we don't know if my advice in that thread was helpful - or if it was discussed with oldman's tax advisor.)
But, as is so often said, "The devil is in the details." And you've given us no details yet.
Also, as I frequently remind readers here, I've been retired for nearly two decades, so be sure to consult with your own CPA or other competent advisor about all this.
RC